Pharmacogenetics of anti-HIV drugs

被引：54

作者：

Telenti, A. ^{[1
]}

Zanger, U. M. ^{[2
,3
]}

机构：

[1] Univ Lausanne, Inst Microbiol, CH-1011 Lausanne, Switzerland

[2] Univ Tubingen, D-72074 Tubingen, Germany

[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2008年 / 48卷

关键词：

protease inhibitors; non-nucleoside reverse transcriptase inhibitors; nucleoside analogue reverse transcriptase inhibitors; HIV susceptibility; ADME proteins;

D O I：

10.1146/annurev.pharmtox.48.113006.094753

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged. A change in paradigm emerges from the availability of the HapMap, the wealth of data on less-common genetic polymorphisms, and new genotyping technology. This review presents a comprehensive analysis of the existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug toxicity, as well as genetic markers associated with the rate of disease progression. It is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future.

引用

页码：227 / 256

页数：30

共 161 条

[91] 'Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients' [J].

Marzolini, C ;

Telenti, A ;

Decosterd, L ;

Biollaz, J ;

Buclin, T .

AIDS, 2001, 15 (09) :1193-1194

[92]

MARZOLINI C, 2005, PHARMACOGENOMICS, P109

[93]

MEHLOTRA RK, 2007, IN PRESS BR J CLIN P

[94] Pharmacogenetics and adverse drug reactions [J].

Meyer, UA .

LANCET, 2000, 356 (9242) :1667-1671

[95] Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain [J].

Miksys, S ;

Lerman, C ;

Shields, PG ;

Mash, DC ;

Tyndale, RT .

NEUROPHARMACOLOGY, 2003, 45 (01) :122-132

[96] Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome [J].

Monaghan, G ;

Ryan, M ;

Seddon, R ;

Hume, R ;

Burchell, B .

LANCET, 1996, 347 (9001) :578-581

[97] Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study [J].

Motsinger, Alison A. ;

Ritchie, Marylyn D. ;

Shafer, Robert W. ;

Robbins, Gregory K. ;

Morse, Gene D. ;

Labbe, Line ;

Wilkinson, Grant R. ;

Clifford, David B. ;

D'Aquila, Richard T. ;

Johnson, Victoria A. ;

Pollard, Richard B. ;

Merigan, Thomas C. ;

Hirsch, Martin S. ;

Donahue, John P. ;

Kim, Richard B. ;

Haas, David W. .

PHARMACOGENETICS AND GENOMICS, 2006, 16 (11) :837-845

[98] Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5 [J].

Mouly, SJ ;

Matheny, C ;

Paine, MF ;

Smith, G ;

Lamba, J ;

Lamba, V ;

Pusek, SN ;

Schuetz, EG ;

Stewart, PW ;

Watkins, PB .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) :605-618

[99] Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia [J].

Mullighan, Charles G. ;

Goorha, Salil ;

Radtke, Ina ;

Miller, Christopher B. ;

Coustan-Smith, Elaine ;

Dalton, James D. ;

Girtman, Kevin ;

Mathew, Susan ;

Ma, Jing ;

Pounds, Stanley B. ;

Su, Xiaoping ;

Pui, Ching-Hon ;

Relling, Mary V. ;

Evans, William E. ;

Shurtleff, Sheila A. ;

Downing, James R. .

NATURE, 2007, 446 (7137) :758-764

[100] Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression [J].

Mummidi, S ;

Ahuja, SS ;

Gonzalez, E ;

Anderson, SA ;

Santiago, EN ;

Stephan, KT ;

Craig, FE ;

O'Connell, P ;

Tryon, V ;

Clark, RA ;

Dolan, MJ ;

Ahuja, SK .

NATURE MEDICINE, 1998, 4 (07) :786-793

← 5 6 7 8 9 10 11 12 13 14 →